Sector News

La Jolla stops pivotal trial, parts company with CEO

November 26, 2019
Life sciences

La Jolla Pharmaceutical has stopped a pivotal trial of LJPC-401 after an interim review. The company disclosed the setback on the same day it revealed its CEO and president George Tidmarsh has left “to pursue other interests.”

LJPC-401, a synthetic form of human iron metabolism regulator hepcidin, moved into a pivotal trial in transfusion-dependent beta thalassemia patients with myocardial iron overload almost two years ago. After enrolling half of the targeted 100 subjects, La Jolla performed an interim analysis that found patients on LJPC-401 were doing no better than their peers on placebo against the primary and key secondary endpoints.

The finding led La Jolla to stop the pivotal trial, killing off near-term hopes of bringing the drug to market in the beta thalassemia population. La Jolla is yet to dump the drug altogether, although it is reassessing whether to continue development.

That response reflects the availability of more encouraging data from a phase 2 study in patients with hereditary hemochromatosis. The trial met its primary endpoint of change in transferrin saturation, which increases in line with the body’s iron stores, and also hit key secondary endpoints, leading La Jolla to characterize results from across the failed and successful studies as “mixed.”

La Jolla is now assessing whether the mixed results justify further investment in LJPC-401. Ultimate responsibility for that decision will fall on a new leader. Tidmarsh, who spent almost eight years at La Jolla, has left the company. La Jolla disclosed the immediate departure of its CEO and president on the same day it shared news of the mixed data on LJPC-401.

Shares in La Jolla fell more than 50% following the one-two punch delivered by the statements.

La Jolla board members Kevin Tang and Craig Johnson will oversee the company’s management team until a new CEO is found. That CEO will inherit a company focused on growing sales of Giapreza, a vasoconstrictor that brought in $15.8 million over the first nine months of the year, and winning FDA approval for malaria drug LJPC-0118.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach